Kid reported Q2/23 EBIT of NOK 66m vs. Factset consensus of NOK 45mPositive deviation explained by strong gross marginOpex-to-sales was 51.1% vs 47.3% in Q2/22LFL sales growth of -3.3% hurt by slowdown in Hemtex
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Kid reported Q2/23 EBIT of NOK 66m vs. Factset consensus of NOK 45mPositive deviation explained by strong gross marginOpex-to-sales was 51.1% vs 47.3% in Q2/22LFL sales growth of -3.3% hurt by slowdown in Hemtex
